Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Sep
03
Today In Oncology
Misconceptions Regarding Skin Cancer Risk in the United States
Advanced Refractory Melanoma Addition of Tilsotolimod to Ipilimumab
Novel Strategy May Enhance Sensitivity of Monitoring Cancer in Blood Samples
Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases
Can ctDNA Monitoring Help to Predict Melanoma Recurrence
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo